Abstract：【Objective】 To investigate the relationship between the level of red blood cells distribution width/erythrocyte sedimentation rate (RDW/ESR), Chemerin , interleukin-13 (IL-13) and coronary dilatation in acute Kawasaki disease.【Methods】A total of 135 children with acute Kawasaki disease treated in our hospital from August 2016 to August 2020 were selected and divided into dilation group (n=28) and non dilation group (n=107) according to whether coronary artery dilation occurred. The baseline data and RDW/ESR, Chemerin and IL-13 of the two groups were compared. The multivariate logistic regression equation was used to analyze the relevant influencing factors of coronary artery dilatation, and the levels of RDW/ESR, Chemerin and IL-13 of children with different therapeutic responsiveness to intravenous immunoglobulin were compared. The receiver operating characteristic curve (ROC curve) was used to analyze the value of each index and combined prediction of therapeutic responsiveness.【Results】RDW/ESR, Chemerin and IL-13 in the expansion group were higher than those in the non expansion group (P<0.05); Multiple logistic regression analysis showed that RDW/ESR, Chemerin and IL-13 were all related to coronary dilatation (P<0.05). The levels of Chemerin and IL-13 in treatment sensitive children were lower than those in non sensitive children (P<0.05). ROC curve showed that the AUC of the combination of Chemerin and IL-13 in predicting IVIG treatment response was higher than that predicted alone, and the AUC was 0.891.【Conclusion】RDW/ESR, Chemerin and IL-13 are all related to coronary artery dilatation in children with acute Kawasaki disease. Chemerin and IL-13 can effectively predict the therapeutic response of intravenous immunoglobulin, and provide basis for timely and effective individualized treatment.
李娜, 韩敏. RDW/ESR、Chemerin、IL-13与急性期川崎病冠脉扩张的相关性[J]. 医学临床研究, 2022, 39(8): 1224-1227.
LI Na, HAN Min. Relationship between RDW/ESR, Chemerin, IL-13 and Coronary Artery Dilatation in Acute Kawasaki Disease. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1224-1227.
2022, Vol. 39 
